CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET ANALYSIS

Chronic Lymphocytic Leukemia Therapeutics Market, by Drug (Idelalisib (Zydelig), Venetoclax (Venclexta), Ibrutinib (Imbruvica), Ofatumumab (Arzerra), Fludarabine (Fludara), Obinutuzumab (Gazyva), Bendamustine Hydrochloride (Treanda), and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa ) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2049
Formats :
Excel and PDF
Industry : Pharmaceutical

Chronic Lymphocytic Leukemia Therapeutics MarketSize and Trends

Chronic Lymphocytic Leukemia Therapeutics Market - Drivers

High prevalence of CLL coupled with its high mortality rate, demonstrates the unmet market need for better therapeutics. According to the American Cancer Society (ACS) estimates, around 20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL is expected in year 2017 in U.S. Furthermore, high prevalence of CLL in geriatric population is expected to increase demand for chronic lymphocytic leukemia therapeutics. According to the United Nations data, in 2015, around 901 million people in the world were over 60 years of age and this number is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.

Market Trends

However, continuous research and development may contribute to the development of new treatments related to malignancies, including impaired immune system, genetic factors, and viruses. Thus expected to boost the market growth during the forecast period.